The FDA has approved Exact Sciences Corp.’s Cologuard Plus test, a next-generation stool DNA test for colorectal cancer (CRC) screening in adults aged 45 and older. This approval is based on the BLUE-C study, demonstrating superior performance compared to its predecessor, Cologuard, and other fecal immunochemical tests. Cologuard Plus will be available in 2025, supported by ExactNexus technology and anticipated Medicare coverage.